| Date | Company | Amount | Funding type | Investors | Therapeutic area | Type of Information |
|---|---|---|---|---|---|---|
| 2017-06-06 | CTI BioPharma (USA - WA) | private placement | Cancer - Oncology | Private placement | ||
| 2017-06-01 | Neurovive Pharmaceutical (Sweden) | 1 million SEK (€ 0.1 million) | grant | Vinnova, Swedish Governmental Agency for Innovation Systems (Sweden) | Rare diseases - Genetic diseases | Grant |
| 2017-06-01 | Flashcell (France) | € 1.5 million | financing round | Auriga Partners (France) Vectalys (France) | Financing round | |
| 2017-05-31 | Achaogen (USA - CA) | $105.4 million | IPO | Infectious diseases | Private placement | |
| 2017-05-30 | Glycomimetics (USA - Md) | $92.6 million | private placement | Cancer - Oncology | Private placement | |
| 2017-05-30 | Albireo Pharma (USA - MA) | $48.2 million | private placement | Gastrointestinal diseases - Digestive diseases - Liver diseases - Hepatic diseases | Private placement | |
| 2017-05-23 | ArgenX (Belgium - The Netherlands) | $114.7 million | IPO | IPO | ||
| 2017-05-16 | Crispr Therapeutics (Switzerland - UK) | grant | Target ALS Foundation (USA) | Neurodegenerative diseases | Grant | |
| 2017-05-16 | Conatus Pharmaceuticals (USA - CA) | $30.6 million | private placement | Hepatic diseases - Liver diseases | Private placement | |
| 2017-05-15 | BiomX (Israel) | €24 million | series A financing round | Johnson & Johnson Development Corporation (USA - NJ) Mirae Asset Global Investments (Republic of Korea) Orbimed (USA – NY) SBI (Japan) Seventure Partners (France) Takeda Ventures (Japan) | Series A financing round | |
| 2017-05-15 | Mabvax Therapeutics (USA - CA) | $4.1 million | private placement | Private placement | ||
| 2017-05-12 | Theradiag (France) | €4,023,994.90 | capital increase | Capital increase | ||
| 2017-05-12 | Theradiag (France) | €4 million | capital increase | Diagnostic - Autoimmune diseases - Immunological diseases | Capital increase | |
| 2017-05-10 | Lonza (Switzerland) | CHF 2.251 billion | capital increase | Technology - Services | Capital increase | |
| 2017-05-08 | Argen-X (Belgium - The Netherlands) | private placement | Private placement | |||
| 2017-05-05 | Amag Pharmaceuticals (USA - MA) | private placement | Private placement | |||
| 2017-05-05 | Achaogen (USA - CA) | up to $20.5 million | grant | Bill & Melinda Gates Foundation (USA) | Infectious diseases | Grant |
| 2017-05-04 | Vivet Therapeutics (France) | €37.5 million | series A financing round | Novartis Venture Fund (Switzerland) Columbus Venture Partners (Spain) Roche Venture Fund (Switzerland), HealthCap (Sweden) Kurma Partners (France) Ysios Capital (Spain) | Rare diseases - Metabolic diseases | Series A financing round |
| 2017-05-02 | Noxxon Pharma (Germany) | € 11 million | capital increase | Cancer - Oncology | Capital increase | |
| 2017-05-02 | Neurocrine Biosciences (US - CA) | $502.2 million | private placement | Neurological diseases | Private placement |
